

### **Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application.

### **Listing of Claims:**

1-17. (cancelled)

18. (New) A peptide consisting of a GLP-1 peptide and Waa-(Xaa)<sub>n</sub>-Yaa (in which Waa is Arg or Lys, Xaa is Lys, n is an integer of 1 to 9, and Yaa is Arg or Arg-NH<sub>2</sub>) added to the C-terminus of the GLP-1 peptide, wherein the GLP-1 peptide is selected from the group consisting of GLP-1(7-35), [Ser<sup>8</sup>]-GLP-1(7-35), [Gln<sup>26</sup>, Asn<sup>34</sup>]-GLP-1(7-35), and [Ser<sup>8</sup>, Gln<sup>26</sup>, Asn<sup>34</sup>]-GLP-1(7-35).

19. (New) The peptide according to claim 18, wherein the GLP-1 peptide is [Ser<sup>8</sup>]-GLP-1(7-35).

20. (New) The peptide according to claim 18, wherein the GLP-1 peptide is [Gln<sup>26</sup>, Asn<sup>34</sup>]-GLP-1(7-35).

21. (New) The peptide according to claim 18, wherein the GLP-1 peptide is [Ser<sup>8</sup>, Gln<sup>26</sup>, Asn<sup>34</sup>]-GLP-1(7-35).

22. (New) The peptide according to claim 18, wherein n is an integer of 3 to 5.

23. (New) The peptide according to claim 18, which has a higher efficiency of transmucosal absorption than that of naturally occurring GLP-1.
24. (New) A pharmaceutical composition for transmucosal administration containing as an active ingredient a peptide consisting of a GLP-1 peptide and Waa-(Xaa)<sub>n</sub>-Yaa (in which Waa is Arg or Lys, Xaa is Lys, n is an integer of 1 to 9, and Yaa is Arg or Arg-NH<sub>2</sub>) added to the C-terminus of the GLP-1 peptide, wherein the GLP-1 peptide is selected from the group consisting of GLP-1(7-35), [Ser<sup>8</sup>]-GLP-1(7-35), [Gln<sup>26</sup>, Asn<sup>34</sup>]-GLP-1(7-35), and [Ser<sup>8</sup>, Gln<sup>26</sup>, Asn<sup>34</sup>]-GLP-1(7-35).
25. (New) The pharmaceutical composition according to claim 24, which is used for nasal administration.
26. (New) The pharmaceutical composition according to claim 24, which is used in treatment of non-insulin dependent chronic diabetes mellitus, treatment of insulin dependent chronic diabetes mellitus, treatment of obesity and/or suppression of appetite.
27. (New) The pharmaceutical composition according to claim 24, wherein the GLP-1 peptide is [Ser<sup>8</sup>]-GLP-1(7-35).
28. (New) The pharmaceutical composition according to claim 24, wherein the GLP-1 peptide is [Gln<sup>26</sup>, Asn<sup>34</sup>]-GLP-1(7-35).

29. (New) The pharmaceutical composition according to claim 24, wherein the GLP-1 peptide is [Ser<sup>8</sup>, Gln<sup>26</sup>, Asn<sup>34</sup>]-GLP-1(7-35).
30. (New) A method for treating non-insulin dependent diabetes mellitus, insulin dependent diabetes mellitus and/or obesity which comprises transmucosally administering to the patient a pharmaceutical composition containing as an active ingredient a peptide consisting of a GLP-1 peptide and Waa-(Xaa)<sub>n</sub>-Yaa (in which Waa is Arg or Lys, Xaa is Lys, n is an integer of 1 to 9, and Yaa is Arg or Arg-NH<sub>2</sub>) added to the C-terminus of the GLP-1 peptide, wherein the GLP-1 peptide is selected from the group consisting of GLP-1(7-35), [Ser<sup>8</sup>]-GLP-1(7-35), [Gln<sup>26</sup>, Asn<sup>34</sup>]-GLP-1(7-35), and [Ser<sup>8</sup>, Gln<sup>26</sup>, Asn<sup>34</sup>]-GLP-1(7-35).
31. (New) The method according to claim 30, wherein the GLP-1 peptide constituting the active ingredient of the pharmaceutical composition is [Ser<sup>8</sup>]-GLP-1(7-35).
32. (New) The method according to claim 30, wherein the GLP-1 peptide constituting the active ingredient of the pharmaceutical composition is [Gln<sup>26</sup>, Asn<sup>34</sup>]-GLP-1(7-35).
33. (New) The method according to claim 30, wherein the GLP-1 peptide constituting the active ingredient of the pharmaceutical composition is [Ser<sup>8</sup>, Gln<sup>26</sup>, Asn<sup>34</sup>]-GLP-1(7-35).